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15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) activates a nuclear receptor heterodimer, peroxisome
proliferators-activated receptor c (PPARc)/ retinoid X receptor (RXRa) through covalent binding
to Cys285 in PPARc ligand-binding domain (LBD). Here, we present the 1.9 Å crystal structure of
C285S mutant LBD complexed with 15d-PGJ2, corresponding to the non-covalently bound state.
The ligand lies adjacent to a hydrogen-bond network around the helix H2 and the nearby b-sheet.
Comparisons with previous structures clariﬁed the relationships between PPARc function and con-
formational alterations of LBD during the process of covalently binding ligands, such as 15d-PGJ2,
and thus suggested a mechanism, by which these ligands modulate PPARc/RXRa function through
conformational changes of the loop following helix H20 and the b-sheet.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Peroxisome proliferators-activated receptor c (PPARc), which
belongs to a nuclear receptor superfamily, functions as obligate
heterodimers with retinoid X receptors (RXRs) [1,2]. This receptor
is particularly noteworthy, because it participates in various bio-
logical phenomena, such as insulin sensitization, adipogenesis,
atherosclerosis, inﬂammation, and carcinogenesis [1,3–7].
PPARc is activated by physiological fatty-acid derivatives,
including nitrated or oxidized fatty acids [8–13]. Several polyun-
saturated lipids, such as 15-deoxy-D12,14-prostaglandin J2 (15d-
PGJ2), activate the receptor-mediated transcription by covalently
binding to a unique cysteine (Cys285) in the ligand-binding do-
main (LBD) [14,15]. Our recent study revealed the following facts
[16]; (1) the covalent binding to endogenous fatty acids, such as
15d-PGJ2, results in the structural alteration of the loop following
helix H20 and in the rearrangement of the side-chain network
around Cys285 within LBD; (2) the conformational difference of
the loop provides the ligand-type speciﬁc effects in term of the dis-chemical Societies. Published by E
-activated receptor c; RXR,
staglandin J2; LBD, ligand-
A-binding domain
. Morikawa).tinct degree of the receptor activity; (3) Phe287, one of these repo-
sitioned residues, has an important role in receptor activation.
However, it has been unclear how the conformational transmission
by non-covalent binding to these ligands modulates receptor func-
tion before covalent bond formation, since the atomic details of the
non-covalently bound state were unavailable.
In this study, we determined the 1.9Å crystal structure of C285S
mutant LBD, which is bound to 15d-PGJ2 in the covalent modiﬁca-
tion-independent manner. The ligand mainly interacts with the
residues on helices H3, H5, and H12, and it is located in the vicinity
of the network of water molecules formed around the helix H2 and
the nearby b-sheet. Comparison of crystal structures of the three
distinct binding states to 15d-PGJ2 [16] showed that the conforma-
tion of the loop following helix H20 changes by non-covalent bind-
ing, and subsequently the side-chain networks around Cys285,
particularly Phe287, are rearranged by covalent binding. This result
indicated that covalently bound ligands might sequentially direct
the ligand-type speciﬁc effects and the switching-on of PPARc acti-
vation, through the two distinct structural alterations. Further-
more, the superposition of the present structure on the crystal
structure of intact PPARc/RXRa complexed with DNA [17] sug-
gested intriguing roles of the 15d-PGJ2 binding pocket in coactiva-
tor recruitment and interactions with the DNA-binding domain
(DBD) of RXRa.lsevier B.V. All rights reserved.
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2.1. Protein preparation
The plasmids and recombinant proteins of the wild type and
C285S mutant human PPARc LBDs (hereafter referred to as wtLBD
and mtLBD, respectively), were prepared as described previously
[15,16]. Using UV absorption spectral analyses [15], we conﬁrmed
that the mtLBD did not bind covalently to 15d-PGJ2 (data not
shown).
2.2. Crystallization, data collection, and model reﬁnement
To avoid variability derived from crystallization conditions and
different crystal packing, we ﬁrst crystallized the mtLBD without
the ligand, under the conditions reported previously [16], and then
soaked the crystals with 15d-PGJ2. The diffraction data were col-
lected at BL38B1 in SPring-8 (Harima, Japan), as described previ-
ously [16]. All data were processed using HKL2000 [18]. The
structure was solved by the molecular replacement method, using
the wtLBD covalently bound to 15d-PGJ2 (PDB ID 2ZK1) as a search
model [16]. The model reﬁnement was carried out using CNS and O
[19,20]. The crystallographic data and reﬁnement statistics are
summarized in Supplementary Table 1. All structural ﬁgures were
made with Chimera [21]. Since helix H12 in monomer B was fre-
quently disoriented, depending upon the crystal packing, we omit-
ted monomer B from the ﬁgure. Coordinates and structural factors
have been deposited in the Protein Data Bank (PDB ID 2ZVT).Fig. 1. Structure of C285S mutant PPARc LBD complexed with 15d-PGJ2. (A) Overall struc
ligand is depicted as a space-ﬁlling model. (B) The composite omit 2|Fo|-|Fc| electron d
represented as stick models. The arrowhead indicates a carbon atom that is potentially c
are represented as spheres, with the composite omit 2|Fo|-|Fc| electron density map con
15d-PGJ2. The ligand is shown by black lines. Hydrophobic interactions are indicated by a
water molecules are represented by ‘‘w”, and are numbered.3. Results
3.1. Structure of C285S mutant PPARc LBD complexed with 15d-PGJ2
The structure of mtLBD complexed with 15d-PGJ2 was reﬁned
at 1.9Å resolution (Fig. 1A). The ﬁnal model of the complex pre-
sented the clear density of 15d-PGJ2 (Fig. 1B). This fatty-acid ligand
was found to interact mainly with helices H3, H5, and H12, and
was located in the close vicinity of the network of water molecules
that adjoins helix H2 and the nearby b-sheet consisting of b2 and
b3. Notably, most of the water molecules within ligand-binding
pocket (LBP) are involved in this network (Fig. 1C and D). This re-
sult indicates that the LBP is divided into hydrophobic and hydro-
philic regions. Hydrogen/deuterium exchange mass spectrometry
experiments revealed that amino acid residues, facing this hydro-
gen-bond network, generally exhibit higher exchange rates than
the other residues [17,19]. The clustering of water molecules
may play some role in enhancing the hydrogen/deuterium ex-
change rates.
3.2. Structural differences among distinct 15d-PGJ2-binding states of
PPARcLBD
To clarify the structure-function relationships of the state with
non-covalently bound 15d-PGJ2, we compared the previously pub-
lished crystal structures of the unliganded wtLBD (PDB ID 2ZK0)
and the wtLBD covalently bound to 15d-PGJ2 (PDB ID 2ZK1) [16]
with the present structure. We ﬁrst focused on the position andture. The Ca atoms of mtLBD are modeled as blue ribbons. The non-covalently bound
ensity map of 15d-PGJ2 (contoured at 1r). The ligand and the Ser285 residue are
ovalently bound to Cys285. (C) Close-up stereo view of LBP. Water molecules in LBP
toured at 1.0r. (D) Schematic representation of the interaction between mtLBD and
rcs, and hydrogen bonds are depicted by dashed lines. Ser285 is colored by red. Key
Fig. 2. Comparisons among various PPARc structures. (A) Superposition of 15d-PGJ2 in the non-covalently bound (blue) and covalently bound (red) states. Hydrogen bonds
between the ligand and Tyr473 are indicated by dashed lines in blue (non-covalently bound state) and red (covalently bound state). The arrowhead indicates the covalent
bond between the ligand and Cys285 in wtLBD. The arrow indicates the carbon atoms that are potentially covalently bound to the cysteine. (B) Root mean square deviation
(RMSD) of the Ca atoms, calculated between the unliganded and non-covalently bound states (blue line) and between the non-covalently and covalently bound states (red
line). The red area represents the loop following helix H20 . Secondary structural elements are indicated at the top. The residues that move more than 8 Å are noted. (C)
Superposition of LBD structures in the three states. The Ca atoms of LBDs are depicted in gray (unliganded state), blue (non-covalently bound state), and red (covalently
bound state). The residues noted in (B) are mapped. (D) The side-chain orientation around Ser285 on helix H3. The side chains among the unliganded, non-covalently bound,
and covalently bound states are depicted in gray, blue, and red, respectively. (E) Schematic model representing the conformational changes of PPARc LBDs during the
activating process by covalently bound ligands. The LBDs are colored in gray (apo state), blue (docked state), and red (locked state), and the ligand is colored green. The loop
following helix H20 is represented as a black line and is named the ‘‘H20–H3 loop”. Phe287 in the apo and docked states is depicted as a blue circle, whereas that in the locked
state is depicted as a red circle. (F) Superposition of the crystal structures of the 15d-PGJ2/mtLBD and the intact PPARc/RXRa with the coactivator peptide on DNA (PDB ID
3DZY). The surfaces in the 15d-PGJ2/mtLBD are colored as follows; the side chains around Phe287 (orange), the loop region following H20 (cyan), and the canonical
coactivator-binding interface (magenta). The white solid line encloses the putative secondary coactivator-binding interface. The red mark represents the interactive region
between PPARc LBD and RXRa DBD in the intact complex.
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between the ligand/LBD complexes with and without the covalent
bond formation revealed that the carboxyl group of the ligand
interacts with the side chain of Tyr473 on helix H12 in each com-
plex (Fig. 2A). This result indicated that the ligand-conﬁgurations
are overall similar before and after the covalent bond formation
with Cys285 in LBD. However, the structure is slightly different
in atomic detail, probably due to a minor environmental change
caused by the substitution of serine for Cys285. It is likely that this
minor difference is alleviated by changes in the torsion angles near
Cys285 during the covalent bond formation.
However, a plotting of the root mean square deviations
(RMSDs) of the Ca atoms versus the residue numbers and a struc-
tural superposition revealed a striking difference in the backbone
structures, conﬁned to the loop following helix H20, between the
apo and non-covalently bound states (Fig. 2B blue line, and C).
On the other hand, the covalent binding caused side-chain rear-
rangements around Cys285, although the backbone structure re-
mained unchanged (Fig. 2B red line, C, and D), indicating that the
covalent modiﬁcation with 15d-PGJ2 alters the local side-chain
network around Cys285.
4. Discussion
4.1. Structural and functional modulation of PPARc by non-covalent
ligand binding
Our earlier study using a cell-based assay revealed that C285S
mutation in PPARc LBD abolished the transcriptional activation
by 15d-PGJ2 [15]. Using the mutant recombinant protein, we have
now presented the 1.9 Å crystal structure of the mutant LBD com-
plexed with the ligand (Fig. 1). This structure is the ﬁrst atomic-de-
tail demonstration of the non-covalently bound, inactive state
before the covalent bond formation during the receptor activating
process (Fig. 2A–D). We recently reported that conformational dif-
ferences in the loop following helix H20 determine the receptor-
activity strength, while several residues, such as Phe287, that shift
due to the covalent modiﬁcation are crucial for the receptor activa-
tion by covalently bound ligands, such as 15d-PGJ2 [16]. Taken to-
gether, the present study indicates that non-covalent binding of
ligands modulates the structure of the loop in the ligand-type spe-
ciﬁc manner, and that covalent binding subsequently induces the
activation by the rearrangement of the side-chain network around
Phe287 (Fig. 2E); the non-covalently bound, inactive intermediate
complex is designated as the ‘‘docked state”, and the covalently
bound and active complex corresponds to the ‘‘locked state”
according to our previous classiﬁcation [22].4.2. Novel modulation of the PPARc/RXRaactivity by covalently bound
ligands
It is well known that hydrogen-bond formation between the
carboxyl group of the synthetic ligand and the side chain of
Tyr473 on helix H12 settles this helix into the active form, thereby
generating the canonical coactivator-binding interface with Lys471
on the same helix and Glu301 on helix H3 [23–25]. Interestingly,
this interaction was found in the present structure, corresponding
to the non-covalently bound, inactive state (Fig. 2A). We conﬁrmed
that the Y473F mutant retains the ability to bind covalently to 15d-
PGJ2 (data not shown), but loses the ligand-induced transcriptional
activity [22]. On the other hand, the C285S mutant cannot be acti-
vated through covalent modiﬁcation, but accommodates the ligand
into LBP [15,22]. Furthermore, our recent report indicated that the
direct interaction with Tyr473 is not always essential for the tran-
scriptional activation by covalently bound ligands [16]. Taken to-gether, these results not only support our proposed model
(Fig. 2E), but also suggest that the interaction with Tyr473 may
transiently stabilize the ligand to take an adequate conﬁguration
for covalent modiﬁcation with Cys285.
A recent report describing the crystal structures of the intact
PPARc/RXRa with ligands and a coactivator peptide on DNA (PDB
ID 3DZY) revealed that b-strand elements S1, S2, and S3 (in this
study, S1 is denoted as b1, and S2 and S3 are b2) and helix H6 in
PPARc LBD interact directly with RXRa DBD [17]. A structural com-
parison indicated that the loop following helix H20 and the side
chains around Phe287 are located in the close vicinity of the
canonical coactivator-binding interface. We previously proposed
that this region might constitute the secondary coactivator-bind-
ing interface [26]. This putative interface occupies a reasonable po-
sition even in the intact receptor complex. Intriguingly, the
hydrogen-bond network and RXRa DBD are located on opposite
sides to each other, across b-sheet consisting of b2 and b3
(Fig. 2F). It is possible that the covalently bound ligands perturb
the hydrogen-bond network, thereby affecting the interaction be-
tween PPARc LBD and RXRa DBD.Acknowledgments
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